{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:53:56Z","timestamp":1789131236830,"version":"build-2803163510"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi230164-4\"><jats:title>Importance<\/jats:title><jats:p>The prognosis for patients with metastatic pancreatic ductal adenocarcinoma (PDAC) is dismal, due in part to chemoresistance. Bacteria-mediated mechanisms of chemoresistance suggest a potential role for antibiotics in modulating response to chemotherapy.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230164-5\"><jats:title>Objective<\/jats:title><jats:p>To evaluate whether use of peritreatment antibiotics is associated with survival among patients with metastatic PDAC treated with first-line gemcitabine or fluorouracil chemotherapy.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230164-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>Using the population-based Surveillance, Epidemiology, and End Results\u2013Medicare linked database, this retrospective cohort study analyzed data for patients diagnosed with PDAC between January 1, 2007, and December 31, 2017. Data analysis was conducted between September 1, 2021, and January 15, 2023. The population-based sample included 3850 patients with primary metastatic PDAC treated with first-line gemcitabine or fluorouracil chemotherapy. Patients who received antibiotics were matched based on propensity scores to patients who did not receive antibiotics.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230164-7\"><jats:title>Exposures<\/jats:title><jats:p>Receipt of 5 or more days of oral antibiotics or 1 injectable antibiotic in the month before or after beginning first-line chemotherapy.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230164-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Overall survival and cancer-specific survival. The end of follow-up was December 31, 2019, for overall survival and December 31, 2018, for cancer-specific survival.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230164-9\"><jats:title>Results<\/jats:title><jats:p>Of the 3850 patients treated with first-line gemcitabine (3150 [81.8%]) or fluorouracil (700 [18.2%]), 2178 (56.6%) received antibiotics. The mean (SD) age at diagnosis was 74.2 (5.8) years and patients were predominantly women (2102 [54.6%]), White (3396 [88.2%]), and from metropolitan areas (3393 [88.1%]) in the northeastern or western US (2952 [76.7%]). In total, 1672 propensity-matched pairs were analyzed. Antibiotic receipt was associated with an 11% improvement in overall survival (hazard ratio [HR], 0.89; 95% CI, 0.83-0.96;<jats:italic>P<\/jats:italic>\u2009=\u2009.003) and a 16% improvement in cancer-specific survival (HR, 0.84; 95% CI, 0.77-0.92;<jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) among patients treated with gemcitabine. In contrast, there was no association between antibiotic receipt and overall survival (HR, 1.08; 95% CI, 0.90-1.29;<jats:italic>P<\/jats:italic>\u2009=\u2009.41) or cancer-specific survival (HR, 1.12; 95% CI, 0.90-1.36;<jats:italic>P<\/jats:italic>\u2009=\u2009.29) among patients treated with fluorouracil. In a subgroup of gemcitabine-treated patients who received antibiotics, nonpenicillin \u03b2-lactams were associated with an 11% survival benefit (HR, 0.89; 95% CI, 0.81-0.97;<jats:italic>P<\/jats:italic>\u2009=\u2009.01).<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230164-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this cohort study, receipt of perichemotherapy antibiotics was associated with improved survival among patients treated with gemcitabine, but not fluorouracil, suggesting that antibiotics may modulate bacteria-mediated gemcitabine resistance and have the potential to improve PDAC outcomes.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.4254","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T15:02:09Z","timestamp":1679583729000},"page":"e234254","source":"Crossref","is-referenced-by-count":48,"title":["Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy"],"prefix":"10.1001","volume":"6","author":[{"given":"Daniel J.","family":"Fulop","sequence":"first","affiliation":[{"name":"Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley M.","family":"Zylberberg","sequence":"additional","affiliation":[{"name":"Division of Digestive and Liver Disease, Department of Medicine, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. Linda","family":"Wu","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Aronson","sequence":"additional","affiliation":[{"name":"Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arielle J.","family":"Labiner","sequence":"additional","affiliation":[{"name":"Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wisnivesky","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre J.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith M.","family":"Sigel","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee L.","family":"Lucas","sequence":"additional","affiliation":[{"name":"Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"issue":"1","key":"zoi230164r1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.v72.1","article-title":"Cancer statistics, 2022.","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"zoi230164r2","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"issue":"18","key":"zoi230164r3","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"19","key":"zoi230164r4","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi230164r5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3390\/cancers9110157","article-title":"Pancreatic cancer chemoresistance to gemcitabine.","volume":"9","author":"Amrutkar","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"19","key":"zoi230164r6","doi-asserted-by":"publisher","first-page":"13054","DOI":"10.1074\/jbc.M114.558924","article-title":"Nucleoside-catabolizing enzymes in mycoplasma-infected tumor cell cultures compromise the cytostatic activity of the anticancer drug gemcitabine.","volume":"289","author":"Vande Voorde","year":"2014","journal-title":"J Biol Chem"},{"key":"zoi230164r7","doi-asserted-by":"publisher","first-page":"14554","DOI":"10.1038\/srep14554","article-title":"Local bacteria affect the efficacy of chemotherapeutic drugs.","volume":"5","author":"Lehouritis","year":"2015","journal-title":"Sci Rep"},{"issue":"6356","key":"zoi230164r8","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1126\/science.aah5043","article-title":"Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.","volume":"357","author":"Geller","year":"2017","journal-title":"Science"},{"issue":"1","key":"zoi230164r9","doi-asserted-by":"publisher","DOI":"10.1080\/23723556.2017.1405139","article-title":"Intratumoral bacteria may elicit chemoresistance by metabolizing anticancer agents.","volume":"5","author":"Geller","year":"2017","journal-title":"Mol Cell Oncol"},{"issue":"2","key":"zoi230164r10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1053\/j.gastro.2022.10.018","article-title":"Gut microbiota modulation of efficacy and toxicity of cancer chemotherapy and immunotherapy.","volume":"164","author":"Chrysostomou","year":"2023","journal-title":"Gastroenterology"},{"issue":"3","key":"zoi230164r11","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.cell.2017.07.008","article-title":"Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy.","volume":"170","author":"Yu","year":"2017","journal-title":"Cell"},{"issue":"4","key":"zoi230164r12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1158\/2159-8290.CD-17-1134","article-title":"The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression.","volume":"8","author":"Pushalkar","year":"2018","journal-title":"Cancer Discov"},{"issue":"2","key":"zoi230164r13","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.bcp.2008.04.019","article-title":"The cytostatic activity of pyrimidine nucleosides is strongly modulated by Mycoplasma hyorhinis infection: implications for cancer therapy.","volume":"76","author":"Bronckaers","year":"2008","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"zoi230164r14","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2017.03.040","article-title":"Host-microbe co-metabolism dictates cancer drug efficacy in C elegans.","volume":"169","author":"Scott","year":"2017","journal-title":"Cell"},{"issue":"6","key":"zoi230164r15","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/bjs.12003","article-title":"Influence of Klebsiella pneumoniae and quinolone treatment on prognosis in patients with pancreatic cancer.","volume":"108","author":"Weniger","year":"2021","journal-title":"Br J Surg"},{"issue":"15","key":"zoi230164r16","doi-asserted-by":"publisher","first-page":"5041","DOI":"10.1002\/cam4.v10.15","article-title":"Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients.","volume":"10","author":"Mohindroo","year":"2021","journal-title":"Cancer Med"},{"issue":"7","key":"zoi230164r17","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1093\/aje\/kwr146","article-title":"Use of Surveillance, Epidemiology, and End Results-Medicare data to conduct case-control studies of cancer among the US elderly.","volume":"174","author":"Engels","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"2","key":"zoi230164r18","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/cam4.2018.7.issue-2","article-title":"Disparities in cancer outcomes across age, sex, and race\/ethnicity among patients with pancreatic cancer.","volume":"7","author":"Nipp","year":"2018","journal-title":"Cancer Med"},{"issue":"5","key":"zoi230164r19","doi-asserted-by":"publisher","first-page":"e659","DOI":"10.1200\/OP.21.00488","article-title":"Opioid prescription is associated with increased survival in older adult patients with pancreatic cancer in the United States: a propensity score analysis.","volume":"18","author":"Zylberberg","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"8","key":"zoi230164r20","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1158\/1055-9965.EPI-17-0227","article-title":"Differential and joint effects of metformin and statins on overall survival of elderly patients with pancreatic adenocarcinoma: a large population-based study.","volume":"26","author":"E","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"10","key":"zoi230164r22","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1101\/gr.107987.110","article-title":"Reshaping the gut microbiome with bacterial transplantation and antibiotic intake.","volume":"20","author":"Manichanh","year":"2010","journal-title":"Genome Res"},{"issue":"5","key":"zoi230164r23","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1080\/19490976.2016.1216747","article-title":"Partial recovery of microbiomes after antibiotic treatment.","volume":"7","author":"Raymond","year":"2016","journal-title":"Gut Microbes"},{"issue":"6","key":"zoi230164r24","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","article-title":"Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non\u2013small-cell lung cancer.","volume":"29","author":"Derosa","year":"2018","journal-title":"Ann Oncol"},{"issue":"6371","key":"zoi230164r25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"issue":"12","key":"zoi230164r26","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1093\/annonc\/mdy453","article-title":"Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials.","volume":"29","author":"Sen","year":"2018","journal-title":"Ann Oncol"},{"issue":"10","key":"zoi230164r27","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/annonc\/mdz206","article-title":"The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?","volume":"30","author":"Elkrief","year":"2019","journal-title":"Ann Oncol"},{"issue":"9","key":"zoi230164r29","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1158\/1055-9965.EPI-19-0021","article-title":"Providing higher resolution indicators of rurality in the Surveillance, Epidemiology, and End Results (SEER) Database: implications for patient privacy and research.","volume":"28","author":"Moss","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"8","key":"zoi230164r30","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1023\/A:1011240019516","article-title":"Socioeconomic status and breast cancer incidence in California for different race\/ethnic groups.","volume":"12","author":"Yost","year":"2001","journal-title":"Cancer Causes Control"},{"issue":"1","key":"zoi230164r31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10552-013-0310-1","article-title":"Using a composite index of socioeconomic status to investigate health disparities while protecting the confidentiality of cancer registry data.","volume":"25","author":"Yu","year":"2014","journal-title":"Cancer Causes Control"},{"issue":"5","key":"zoi230164r32","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"6","key":"zoi230164r33","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/sim.v33.6","article-title":"A comparison of 12 algorithms for matching on the propensity score.","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"issue":"1","key":"zoi230164r34","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research.","volume":"15","author":"Chesnaye","year":"2021","journal-title":"Clin Kidney J"},{"issue":"6","key":"zoi230164r35","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/0016-5085(92)91450-I","article-title":"Human pancreatic tissue concentration of bactericidal antibiotics.","volume":"103","author":"B\u00fcchler","year":"1992","journal-title":"Gastroenterology"},{"key":"zoi230164r28","author":"Kury","year":"2016"},{"key":"zoi230164r21","unstructured":"National Cancer Institute. Observational research oncology toolbox. Cancer Medications Enquiry Database (CanMED). Accessed October 10, 2021. https:\/\/seer.cancer.gov\/oncologytoolbox\/canmed\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2802747\/fulop_2023_oi_230164_1678906343.61.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T13:44:36Z","timestamp":1702129476000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2802747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.4254","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,23]]}}}